Hospital Acquired Infections: Testing Markets

   Single User - $3,995
   Site License (one location, 10 users) - $5,750
   Corporate License - $7,990

Published Aug 14, 2012 | 117 Pages | Pub ID: KLI4861606

A nosocomial, or hospital-acquired, infection is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections). The following are among the hospital infections considered in this report:
  • Acinetobacter Baumannii
  • Clostridium Difficile
  • Hospital-Acquired Pneumonia
  • Pseudomonas Aeruginosa
  • Staphylococcus Aureus
  • Tuberculosis
  • Urinary Tract Infections
  • Vancomycin-resistant Enterococcus
  • Ventilator-Associated Pneumonia
This report focuses on testing for nosocomial infections. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningful based both on medial considerations and on market considerations. This report Hospital Acquired Infection Testing Markets looks at the market for diagnostics that address the growing nosocomial infection threat. As part of its coverage, the report includes the following information:
  • Market Size Estimate and Growth Forecast for the HAI Diagnostics Market
  • Issues and Trends Affecting Market
  • Common Hospital (nosocomial) Infections
  • Nosocomial Infection Statistics
  • International Hospital Length of Stay Statistics
  • The Role of Molecular Tests vs. Traditional
  • Corporate Profiles of Key Suppliers

Market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing and treatment needs.

The primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for diagnosing these infections. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.

Companies Profiled in the report include the following:
  • Abbott Laboratories
  • Alere
  • Becton, Dickinson
  • bioMerieux
  • Cephei
  • Gen-Probe
  • Meridian Bioscience, Inc.
  • Qiagen GmbH
  • Roche
  • Siemens AG

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times